Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The regimen of oral Xeloda with two-way bi-platinu (intravenous and intraperitoneal administration) to treat advanced gastrointestinal cancer had better short-term and long-term effects in comparison with the standard treatment in China. Therefore, it was an effective, safe, and economic regimen for these patients.